OVA Peptide (323-339) is an immunodominant epitope peptide derived from chicken ovalbumin (OVA), which is the major MHC class II-restricted T-cell epitope that specifically binds H2-IAd molecules, and a B-cell epitope that is recognized by IgE antibodies. It is commonly used in the study of egg allergy, and is able to induce strong Th2-type immune responses and IgE antibody production in mice.

OVA Peptide(257-264) is an ovalbumin octamer Peptide expressed by class I MHC molecule h-2kb.

SIIVFEKL TFA is a variant of the principal MHC class I-restricted epitope, SIINFEKL. This antigenic peptide stimulates specific T cells in experimental settings to study competitive interactions among T cells. SIIVFEKL TFA exhibits lower affinity for the OT-I T cell receptor (TCR) and can be utilized to detect CD8+ T cells.

WT1 126-134 peptide is a WT1 polypeptide (Wilms' tumor 1 peptide) (RMFPNAPYL) that activates cytotoxic CD8 T cells to target and destroy WT1+ tumor cells. It can form stable complexes with either H-2Db (murine) or HLA-A0201 (human) molecules. The WT1 126-134 peptide/HLA-A0201 complex exhibits high affinity for humanized monoclonal antibodies (IgG1), with a dissociation constant (Kd) of 0.2 nM. This peptide can be utilized as a T cell vaccine or an antibody target.

OVA(250-264) (OVAvac) (OVAp) is an antigenic peptide derived from chicken egg ovalbumin, presented by class I MHC molecule H-2Kb. This peptide, when combined with αMSLN (anti-MSLN antibody), significantly stimulates the production and infiltration of antigen-specific CD8+ T cells, thereby enhancing antitumor effects in an in situ pancreatic cancer mouse model. It is applicable in developing tumor neoantigen vaccines for pancreatic cancer immunotherapy research.

Anti-HLA-A2 (Hu8F4) is a human-derived monoclonal antibody (mAb) that targets HLA-A2. It is applicable in the study of acute myeloid leukemia. The recommended isotype control is Human IgG1 kappa (Isotype Control).

OVA Peptide (257-264) TFA, an octameric peptide epitope from ovalbumin, is presented by the class I MHC molecule, H-2Kb, showcasing a class I (Kb)-restricted profile.

Decamethylene glycol is a substance used as a reagent in the biological study of modified oligonucleotide with in vivo antitumoral activity. Also used in the pharmaceutical study on the composition of essential oils obtained from myrrh and frankincense an

GAD65 (206-220) is a synthetic peptide derived from glutamic acid decarboxylase (GAD) 65, specifically corresponding to residues 180-188. It is known that GAD65 interacts with I-Ag7 MHC class II molecules and is a significant pancreatic antigen that self-reactive T cells target in type I diabetes mellitus.

D-α-Methyl DOPA is an inhibitor of DQ8 peptide binding to MHC class II molecules. By occupying a binding site in the DQ8 peptide groove, D-α-Methyl DOPA prevents the DQ8 peptide from associating with MHCII molecules. This action blocks presentation to CD4+ T cells, thereby slowing or hindering the onset or progression of type 1 diabetes or celiac disease.

AS2677131 is a potent and orally active PIKfyve inhibitor. It suppresses IL-12p40, IL-6, and IL-1β through the PIKfyve-c-Rel pathway and selectively inhibits the DNA-binding activity of c-Rel with IL-12p40 and IL-1β promoters. Additionally, AS2677131 represses the expression of MHCII molecules on B cells. This compound is applicable for research in inflammation and immunology, such as in arthritis.

OVA Peptide(257-264) acetate salt is a Class I (Kb)-restricted epitope of OVA. This octamer peptide is presented by Class I MHC molecule H-2Kb derived from ovalbumin.

Z-Val-Val-Nle-diazomethylketone is an inhibitor of cathepsin S (CATS). It significantly suppresses the upregulation of IFNg-induced MHCII molecules, specifically HLA-DR and Ii-p33/35, while increasing the protein level of Ii-p10. This compound can be utilized for research into skin disorders such as psoriasis, atopic dermatitis, and actinic keratosis.

Smcy HY Peptide (738-746) is an H2-Db-restricted peptide derived from amino acids 738 to 746 of the Smcy protein.

Ovalbumin (OVA) peptide, primarily found in egg white, is a class I (Kb)-restricted peptide epitope presented by H-2Kb, the mouse MHC (major histocompatibility complex) class I gene product. It has garnered significant attention in the field of allergy research [1] [2].

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is an IgG2a, κ antibody inhibitor derived from mice that targets monkey or human MHC class II.

IRBP (1-20), human is the 1-20 fragment of interphotoreceptor retinoid binding protein (IRBP).This peptide is a 1 to 20 amino acid fragment of the interphotoreceptor retinoid binding protein (IRBP). IRBP is a 140-kDa glycolipoprotein residing in the inter

PADRE peptide is a universal peptide epitope. It binds to the pan HLA-DR receptor on specific T cells. PADRE peptide can be incorporated into either the Trichodysplasia Spinulosa-associated polyomavirus (TSPyV) VP1 protein or hamster polyomavirus (HaPyV)-derived VP1 to construct chimeric virus-like particles (VLPs), thereby activating dendritic cells and T cells and inducing a strong immune response. PADRE peptide is useful in vaccine development.

BAGE (2-10) is a nonapeptide encoded by the BAGE gene. It binds with HLA-Cw*1601 molecules to form an antigen recognized by autologous cytotoxic T lymphocytes. BAGE (2-10) is applicable in melanoma research.

GFKQSSKAL is an e14a2 junction sequence that binds effectively with HLA-B8. This compound is useful for research in chronic myeloid leukemia.

VLPDVFIRCV, a peptide derived from a melanoma antigen, originates from the intronic sequence (nt 38-67) of the N-acetylglucosaminyltransferase V (GnT-V) gene. Despite its high binding affinity for MHC-I molecules, VLPDVFIRCV does not activate an immune response against natural tumor cells. However, cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in chromium release assays. This peptide is useful for research in vaccine design.

Isuventatug is a monoclonal antibody that targets human MICA (MHC I chain-related molecule A) and MICB (MHC I chain-related molecule B). By binding to MICA and MICB, Isuventatug modulates the interaction between immune cells and tumor cells, exhibiting anti-tumor activity. This compound holds potential for research in cancer immunotherapy.

Anti-Rat β-2-Microglobulin Antibody (4C9) is an IgG1 antibody inhibitor derived from mice, targeting rat β-2-Microglobulin.

1D09C3 is a fully humanized anti-HLA-DR monoclonal antibody. It induces cell apoptosis (apoptosis) and death through a cascade of reactions, including reactive oxygen species (ROS) production, JNK activation, mitochondrial membrane depolarization, and the release of AIF from mitochondria. In xenograft models with JVM-2 cells and GRANTA-519 cells in mice, 1D09C3 demonstrated significant antitumor activity, improving overall survival and median survival time. This compound is applicable in cancer research, including studies on chronic lymphocytic leukemia (CLL).